Literature DB >> 8955852

Inhibition of human immunodeficiency virus replication by the sulfonated stilbene dye resobene.

S M Halliday1, C Lackman-Smith, J P Bader, W G Rice, D J Clanton, L H Zalkow, R W Buckheit.   

Abstract

The anti-HIV sulfonated dye, resobene, was found to be a potent inhibitor of the attachment of HIV to target cells, the fusion of envelope- and CD4-expressing cells, and the cell-to-cell transmission of virus. Resobene inhibited the infection of phenotypically distinct, established human cell lines and fresh human peripheral blood lymphocytes and macrophages by laboratory-derived isolates of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2), and a panel of biologically diverse primary clinical isolates, including syncytium-inducing and non-syncytium-inducing viruses and strains representative of the various virus clades found worldwide. The compound was also active against all drug-resistant virus isolates tested. Cell-based and biochemical mechanism of action studies demonstrated that the compound inhibits the attachment of infectious virus and fusion of virus-infected cells to uninfected target cells by binding to the cationic V3 loop of the envelope glycoprotein. Resobene effectively inhibited the infection of cell populations which do and do not express cell surface CD4. Resobene prevented infection of the cervical epithelial cell line ME180, suggesting the compound may effectively act as a topical microbicide to prevent the sexual transmission of HIV.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8955852     DOI: 10.1016/s0166-3542(96)00994-1

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  6 in total

Review 1.  Protein recognition using synthetic surface-targeted agents.

Authors:  Rishi Jain; Justin T Ernst; Olaf Kutzki; Hyung Soon Park; Andrew D Hamilton
Journal:  Mol Divers       Date:  2004       Impact factor: 2.943

2.  Antiviral activity of retrocyclin RC-101, a candidate microbicide against cell-associated HIV-1.

Authors:  Phalguni Gupta; Carol Lackman-Smith; Beth Snyder; Deena Ratner; Lisa C Rohan; Dorothy Patton; Bharat Ramratnam; Alexander M Cole
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-10       Impact factor: 2.205

3.  Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide.

Authors:  R W Buckheit; E L White; V Fliakas-Boltz; J Russell; T L Stup; T L Kinjerski; M C Osterling; A Weigand; J P Bader
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

4.  Development of dual-acting pyrimidinediones as novel and highly potent topical anti-HIV microbicides.

Authors:  Karen Watson Buckheit; Lu Yang; Robert W Buckheit
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

5.  Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.

Authors:  Carol Lackman-Smith; Clay Osterling; Katherine Luckenbaugh; Marie Mankowski; Beth Snyder; Gareth Lewis; Jeremy Paull; Albert Profy; Roger G Ptak; Robert W Buckheit; Karen M Watson; James E Cummins; Brigitte E Sanders-Beer
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

6.  Comparative evaluation of virus transmission inhibition by dual-acting pyrimidinedione microbicides using the microbicide transmission and sterilization assay.

Authors:  Karen M Watson; Christa E Buckheit; Robert W Buckheit
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.